ML-355 Drug Asset Due Diligence Report 2026

This ML-355 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether ML-355 can convert its Small molecule drug profile and ALOX12 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	ML-355 (query alias: ML-355)
Modality / target	Small molecule drug; ALOX12; ALOX12 inhibitors
Highest global status	Phase 2
Originator	Veralox Therapeutics, Inc.
Active developers	Veralox Therapeutics, Inc., The University of Chicago, Cadrenal Therapeutics, Inc.

The MCP disease footprint includes Heparin-induced thrombocytopenia, Diabetes Mellitus, Type 2, Obesity. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05785819	Phase 2	Terminated	24	Primary endpoint not disclosed in English source
NCT05325346	Phase 1	Completed	12	Primary endpoint not disclosed in English source
NCT04783545	Phase 1	Completed	96	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

Phase 2; n=24; evaluation: Positive. Reported fields: platelet count recovery = imilar between，did not appear to be a surrogate marker for clinical efficacy. ; platelet count recovery = imilar between，did not appear to be a surrogate marker for clinical efficacy.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

ML-355 addresses Heparin-induced thrombocytopenia, Diabetes Mellitus, Type 2, Obesity. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-12-11	Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)	Phase 2	Financial terms not disclosed
Not disclosed	Veralox Therapeutics, Inc. acquires Nudge Therapeutics	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods for treating heparin-induced thrombocytopenia”. The milestone feed surfaced a patent-application signal described as “12-lipoxygenase inhibitors for the treatment of lupus”. The milestone feed surfaced a patent-application signal described as “Oral pharmaceutical formulations containing 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO